We are live on
!
Find out more
WCM
Wildcat Capital Management Portfolio holdings
AUM
$229M
1-Year Est. Return
132.65%
This Fund
S&P 500
This Quarter
Est. Return
+16.54%
1 Year Est. Return
+132.65%
3 Year Est. Return
+125.67%
5 Year Est. Return
+54.1%
10 Year Est. Return
+1,929.91%
AUM
$94M
AUM Growth
-$464M
(-83%)
Cap. Flow
-$474M
Cap. Flow
% of AUM
-504.55%
Top 10 Holdings %
Top 10 Hldgs %
99.35%
Holding
18
New
2
Increased
1
Reduced
5
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AppFolio
APPF
|
+$2.57M |
| 2 |
SBR
Sabine Royalty Trust
SBR
|
+$2.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KITE
Kite Pharma, Inc.
KITE
|
+$433M |
| 2 |
ImmunityBio
IBRX
|
+$12.2M |
| 3 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$8.09M |
| 4 |
CoStar Group
CSGP
|
+$6.98M |
| 5 |
UNIT
Uniti Group
UNIT
|
+$6.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 48.34% |
| 2 | Financials | 12.67% |
| 3 | Energy | 11.3% |
| 4 | Healthcare | 8.9% |
| 5 | Communication Services | 3.52% |
Similar funds
AFO
CNHF
GCM
CM
CSIA
AF
NIA
HFA
Wildcat Capital Management's Q4 2017 Portfolio in Review
As of Q4 2017, Wildcat Capital Management held 18 positions worth $94M, down 83% from $558M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Wildcat Capital Management withdrew a net $474M in Q4 2017, closing 7 positions and reducing 5 holdings. Its most notable exit was Kite Pharma, Inc., an estimated $433M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 48% of assets, up from 9.6% a quarter earlier, followed by Financials and Energy.
Against the trend, Wildcat Capital Management opened a new position in AppFolio worth $2.38M.
- Wildcat Capital Management's largest Q4 2017 buy was AppFolio: 57,372 shares worth $2.38M.
- Wildcat Capital Management added most to Sabine Royalty Trust in Q4 2017, an estimated $2.27M increase.
- Wildcat Capital Management's biggest Q4 2017 reduction was ImmunityBio, cutting an estimated $12.2M.
- Wildcat Capital Management fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $433M.
- Wildcat Capital Management's ten largest holdings make up 99% of its $94M portfolio in Q4 2017.
- Wildcat Capital Management opened 2 new positions and closed 7 in Q4 2017.
- Wildcat Capital Management's portfolio value fell 83% quarter-over-quarter to $94M.
Based on Wildcat Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.